3 results
Prazosin for the treatment of Obsessive Compulsive Disorder:
An open label, fixed dose add-on study.
To determine whether the addition of the *1 adrenoreceptor antagonist prazosin to SSRI is useful for patients with OCD who do not respond to SRI monotherapy.
Approved WMOCompleted
Part 1: To evaluate the effects of BIIB033 versus placebo on disability improvement over 72 weeks.Part 2: evaluate long-term safety profile of BIIB033 as an add-on therapy in subjects with MS.
Approved WMOCompleted
To demonstrate non-inferiority of a T2T strategy in which conventional synthetic disease modifying drugs (csDMARDs) refractory RApatients are initially treated with tsDMARD baricitinib versus the comparable T2T strategy in which patients areā¦